Team fighting treatment resistance in non-small cell lung cancer
BAY AREA & ANDERSON TEAM AGAINST ACQUIRED RESISTANCE - U54 PROGRAM (BAATAAR-UP)
Finding ways to stop non-small cell lung cancers from becoming resistant to targeted and immune therapies using patient samples and models.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11190976 on NIH RePORTER |
What this research studies
We will study tumors together with the surrounding cells to map how they change during treatment. Using clinical samples from patients and patient-derived laboratory models, researchers will trace the cellular and signaling networks that let tumors survive targeted drugs (for example EGFR and KRAS G12C inhibitors) and immune therapies. The team will test strategies that exploit weak points in that tumor ecosystem to prevent or reverse resistance. Work aims to point to new combination treatments and biomarkers to help doctors choose better therapies.
Who could benefit from this research
Good fit: People with non-small cell lung cancer, especially those receiving or who have received targeted drugs (like EGFR or KRAS G12C inhibitors) or immunotherapy, are the best candidates.
Not a fit: People without non-small cell lung cancer or those whose tumors lack targetable mutations are unlikely to be directly helped by this program.
Why it matters
Potential benefit: Could lead to combination treatments or strategies that make targeted and immune therapies work longer for people with NSCLC.
How similar studies have performed: Prior studies have identified some resistance mechanisms and effective combinations, but many resistance pathways are still new and this program builds on both confirmed and novel findings.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Bivona, Trever G — University of California, San Francisco
- Study coordinator: Bivona, Trever G
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.